Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update Read more about Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Read more about Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch Read more about Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update Read more about Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read more about Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch Read more about Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update Read more about Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update Read more about Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update Read more about Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity Read more about Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity